Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study

Friedreich Ataxia Clinical Trial

— UNIFAI  

Official title:

Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06016946
• Other study ID #: 1016
• Status: Recruiting
• Start date: June 28, 2023
• Est. completion date: January 28, 2048

Study information

• Verified date: April 2024
• Source: Friedreich's Ataxia Research Alliance
• Contact: Cait Monette
• Phone: 16513291892
• Email: cait.monette[@]cureFA.org
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This project is a global, multicenter, prospective, longitudinal, observational natural history study that can be used to understand the disease progression and support the development of safe and effective drugs and biological products for Friedreich ataxia.

Description:

The UNIFAI Study: Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study is a global research study designed to provide a deep and evolving understanding of the natural history of this rare and debilitating genetic disorder as well as inform clinical trial design and implementation. Friedreich's Ataxia is a rare, inherited, multi-system condition characterized by progressive neurological and cardiac symptoms. It is caused by mutations in the FXN (frataxin) gene. The UNIFAI study is a multicenter, prospective, longitudinal, observational study, which means that all data about the natural disease course will be captured at study visits conducted annually according to a single protocol for all sites. This study will recruit participants with FA worldwide, to be assessed annually for up to 25 years. Study participation involves yearly study visits with data collected from medical records and history along with clinical outcome assessments including, neurological exams, timed walking tests, upper limb function measures, and patient-reported quality of life assessments, with the option for sites to collect additional ancillary measures related to speech, vision, fatigue, balance and cognition. This global study is a harmonization of two well-established, long-standing natural history studies in FA that have provided a framework for further investigation of clinical measures that can quantitatively assess FA: FACOMS (US, Canada, Australia, New Zealand, and India) and EFACTS (European countries). These studies have been conducted in parallel with many similarities in study conduct. Uniting these two existing studies and groups of researchers gives greater power to data previously collected as well as future data. It also continues efforts to expand the network of clinical research centers specializing in FA called the FA-Global Clinical Consortium. Due to advances in understanding the genetic and cellular dysfunction of FA that lead to symptoms observed in affected individuals, there has been significant growth in the discovery and development of therapeutic approaches, many currently being evaluated in clinical trials and a first approved treatment in the United States in 2023. The UNIFAI study aims to build upon this momentum by focusing on several key objectives. UNIFAI will assess the natural history of FA by collecting data from diagnosed individuals of all ages and stages of disease progression. The data collected includes demographics, medical history, medications, neurological and functional assessments, cardiac examinations, laboratory studies, and health questionnaires. The study will assess and evaluate clinical outcomes in individuals with FA, such as disease progression, symptom severity, and overall quality of life, by various factors that might influence such outcomes such as genetic mutation, demographics (age, geography), co-existing conditions, medications, or treatments. By tracking outcomes over time, researchers aim to discern patterns, trends, and potential variations in subgroups or in the effectiveness of therapies or interventions across a diverse group of participants. The UNIFAI study aims to play a pivotal role in identifying clinical milestones and changes in natural history over time as new treatments emerge. The study will monitor how these interventions alter the trajectory of the disease, potentially leading to the identification of crucial tipping points, disease landmarks, or stages where interventions can be most impactful. This study has the potential to significantly improve our understanding of FA and lead to more effective treatments and improved outcomes for those living with FA. The study aims to inform clinical trial design and the development and validation of novel clinical outcome assessments and biomarkers that can be used in clinical trials. The UNIFAI study aims to capture data from a wide and diverse cohort of individuals with FA so that this dataset can be used to inform the selection of inclusion and exclusion criteria and power calculations for trial designs with specific clinical outcome measures.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3000
• Est. completion date: January 28, 2048
• Est. primary completion date: January 28, 2048
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Both males and females of any age

2. Individuals with Friedreich ataxia (FA): Participants that meet genetically confirmed diagnosis of Friedreich ataxia

3. Written informed consent provided

1. Informed consent must be obtained for all participants

2. For underage participants, they and the parent/ legally authorized representative have to sign the informed consent form, child assent (if applicable)

3. Persons who are not legally competent require the informed consent of their legally authorized representative

Exclusion Criteria:

4. Unable or unwilling to provide informed consent

5. Acute or ongoing medical or other conditions that would interfere with the conduct and assessments of the study

6. For any reason in the opinion of the investigator, participant would be unlikely or unable to comply with study protocol requirements.

Related Conditions & MeSH terms

• Ataxia
• Cerebellar Ataxia
• Friedreich Ataxia

Locations

Country	Name	City	State
Australia	Murdoch Childrens Research Institute	Parkville	Victoria
Austria	Medical University Innsbruck, Department of Neurology	Innsbruck
Belgium	Université Libre de Bruxelles, Hôpital Erasme, Dpt of Neurology	Bruxelles
Brazil	University of Campinas	Campinas
Canada	McGill University Health Centre - Montreal Neurological Institute	Montreal	Quebec
Canada	CHUM - Hopital Notre-Dame	Montréal	Quebec
Canada	The Hospital for Sick Children	Toronto	Ontario
Czechia	Motol University Hospital, Centre for Hereditary Ataxias	Praha
France	Paris Brain Institute	Paris
France	Hôpital de Hautepierre, Service de Neurologie	Strasbourg
Germany	University Hospital Aachen, Dept. of Neurology	Aachen
Germany	Deutsches Zentrum Für Neurodegenerative Erkrankungen	Bonn
Germany	University of Munich, Dept. of Neurology, Friedrich-Baur-Institut	Munich
Germany	University of Tübingen, Dept. of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research	Tübingen
Greece	National and Kapodistrian University of Athens, Neurogenetics Unit	Athens
India	All India Institute of Medical Sciences (AIIMS)	New Delhi	NCT
Ireland	Tallaght University Hospital, Department of Neurology	Dublin
Italy	Referente Clinico-Scientifico di Polo IRCCS "E. Medea"	Conegliano
Italy	Fondazione IRCCS Istituto Neurologico Carlo Besta	Milan
Italy	Bambino Gesù Children's Hospital, Department of Neurosciences	Roma
Netherlands	Stichting Radboud Universitair Medisch Centrum	Nijmegen
New Zealand	Auckland City Hospital	Auckland
Spain	Hospital Sant Joan de Déu, Servicio de Neurología	Barcelona
Spain	Hospital Universitario La Paz, Servicio de Neurologia	Madrid
United Kingdom	University College of London, Ataxia Centre, National Hospital for Neurology and Neurosurgery	London
United States	Emory University Hospital - Neurology	Atlanta	Georgia
United States	Ohio State University - Neurology	Columbus	Ohio
United States	University of Colorado	Denver	Colorado
United States	University of Florida - Neurology	Gainesville	Florida
United States	University of Iowa, Stead Family Children's Hospital	Iowa City	Iowa
United States	UCLA Ataxia Center	Los Angeles	California
United States	St. Jude Children's Research Hospital	Memphis	Tennessee
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	USF Ataxia Research Center	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Friedreich's Ataxia Research Alliance

Countries where clinical trial is conducted

United States,  Australia,  Austria,  Belgium,  Brazil,  Canada,  Czechia,  France,  Germany,  Greece,  India,  Ireland,  Italy,  Netherlands,  New Zealand,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in modified Friedreich Ataxia Rating Scale (mFARS) Score	The modified Friedreich Ataxia Rating Scale (mFARS) is a disease-specific scale that measures progression of neurological effects of FA. The mFARS is a validated and reliable scale; comprised of the neurologic component of the FARS and evaluates bulbar, upper limb, lower limb, and upright stability/gait function. For each item, responses categorize the corresponding neurological finding, and the findings are assigned a score ranging from 0 to 3, 4, or 5 with 0 being normal and higher numbers indicative of greater impairment. The score ranges from 0 to 93. The score will be compared to the previous year annually for up to 25 years.	Baseline, Year 1-25
Primary	Change in Scale for the Assessment and Rating of Ataxia (SARA) Score	The Scale for the Assessment and Rating of Ataxia (SARA) is a semi-quantitative assessment of ataxia, measuring ataxia of upper limb, lower limb, gait, balance and speech. It has eight items: gait, stance, sitting, speech disturbance, finger chase, nose-finger test, fast alternating hand movement, and heel-shin slide. The total score ranges from 0 (no ataxia) to 40 (severe ataxia). The score will be compared to the previous year annually for up to 25 years.	Baseline, Year 1-25
Primary	Change in FA Activities of Daily Living (ADL) Score	The FARS-ADL is a subsection of the FARS questionnaire that assesses activities of daily living, including speech, personal hygiene, feeding, and mobility. Participants rank each category using a scale of 0 (normal) to 4 (severe disability/ inability to carry out activity independently), with lower scores indicative of "normal" function/activity. The score will be compared to the previous year annually for up to 25 years.	Baseline, Year 1-25
Primary	Change in Upright Stability (US) Score	The Upright Stability (US) assessment is part of the neurological examination within the Modified Friedreich Ataxia Rating Scale (mFARS). This component comprises nine items: sitting position, stance with feet apart, stance with feet apart and eyes closed, stance with feet together, stance with feet together and eyes closed, tandem stance, stance with dominant foot, tandem walk, and gait. The score ranges from 0 to 9, with a higher score reflecting poorer upright stability (i.e., greater neurological severity). The score will be compared to the previous year annually for up to 25 years.	Baseline, Year 1-25
Secondary	Change in 9-hole peg test mean time (seconds)	The 9 Hole Peg Test (9HPT) examines finger dexterity and involves placing and removing nine pegs in a pegboard in the quickest possible time. Two consecutive trials of the dominant hand, followed immediately by two consecutive trials of the non-dominant hand, are undertaken. The average time in seconds taken to complete the task, for each of the dominant and non-dominant hand, is calculated. The 9HPT has high intra- and inter-rater reliability and is the most commonly used measure of upper limb function in FA. The score will be compared to the previous year annually for up to 25 years.	Baseline, Year 1-25
Secondary	Change in Timed walk (25-foot or 8-meter) mean time (seconds)	The timed 25-foot/8-meter walk examines upright stability, balance and mobility and involves walking a predetermined distance. Two consecutive trials are undertaken. The average time in seconds taken to complete the task, is calculated. The score will be compared to the previous year annually for up to 25 years.	Baseline, Year 1-25
Secondary	Change in Speech analysis scores	A battery of speech evaluations will be administered and recorded on a laptop for analysis, using Redenlab software. This will include: reading of a phonetically-balanced passage, sustained vowel sound, listing days of the week, repeating syllables, and a monologue task. This will form a measure of dysarthria. Redenlab is a US-Australian speech-testing company, https://redenlab.com. The score will be compared to the previous year annually for up to 25 years.	Baseline, Year 1-25
Secondary	Change in Ataxia Instrumented Measures (AIMs)clinical severity score	The Ataxia Instrumented Measures (AIMs) system consists of three components: 1) the data logger which is either a spoon, cup or pendant each containing sensors, Wi-Fi and processor; 2) algorithms that distinguishes between movements made by control and users with ataxia and grades the severity of ataxia when detected; and 3) ataxia scores presented in a manner that has utility for clinicians (the AIM "score"). This score is continuous and features an ataxia severity threshold which has been established through the process of machine learning and is based on the separation between individuals with ataxia and control participants. Any value below the severity threshold of a specific device is expected for controls/very mild ataxia, and any value beyond is expected for individuals with moderate/severe ataxia. The score will be compared to the previous year annually for up to 25 years.	Baseline, Year 1-25
Secondary	Change in Lower Contrast Letter Acuity test score	Contrast letter acuity for vision will be assessed using back-lit Low-Contrast Sloan Letter Charts (LCSLCs). Participants will sit at an eye distance of 2 metres from the chart. Binocular vision will be assessed using participants' normal corrective lenses where relevant. Participants are required to read each letter on the chart. Three charts will be presented, with three different visual contrast levels: 100% (equivalent to high-contrast visual acuity), 2.5%, and 1.25%. The maximum total score across the three charts (number of letters read correctly) is 240. Scores for each individual chart will also be recorded.	Baseline, Year 1-25